Business Context and Reporting Period
Calidi Biotherapeutics, Inc. (CLDI) filed this Form 8-K on July 11, 2025, reporting on events occurring on July 9, 2025. The filing details the results of the Company's 2025 Annual Meeting of Stockholders. As of the record date of May 19, 2025, there were 31,792,580 shares of Common Stock issued and outstanding.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and stockholder actions. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Voting Results
At the Annual Meeting, 16,932,481 shares (approximately 53.26% of entitled shares) were represented, constituting a quorum. All four proposals presented were approved:
- Election of Directors: James Schoeneck and George Peoples were elected as Class II Directors for a three-year term.
- Auditor Ratification: Stockholders ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Reverse Stock Split Authorization: Stockholders approved an amendment to the Certificate of Incorporation authorizing the Board to effect a reverse stock split at a ratio between 1-for-2 and 1-for-19 at its discretion.
- Equity Plan Amendment: Stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the aggregate number of shares authorized for grant from 393,780 to 3,393,780.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The primary contingency noted is the Board's future discretion to determine the specific ratio of the reverse stock split within the approved range (1-for-2 to 1-for-19) and the timing of its implementation.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once announced by the Board.
- Monitor the impact of the increased equity pool (3,393,780 shares) on future dilution.
- Confirm the composition of the Board of Directors following the election of Schoeneck and Peoples.
- Review upcoming financial reports for the fiscal year ending December 31, 2025, to assess liquidity and operational progress.